About PreScience Labs
PreScience is a developmental stage bio-pharmaceutical company focused on developing anti-cancer drugs. It has successfully completed preclinical mechanistic, in vitro and animal testing using intra-arterial delivery of its proprietary drug PSL-001. In January, 2013, the FDA approved immediate enrollment of a Phase I study, which PreScience intends to initiate at leading US cancer centers in 2015. The study will recruit primary and metastatic liver cancer patients.
PreScience is also developing a systemic formulation with the goal of maintaining efficacy and potency without increase in toxicity. This new formulation is designed to protect 3–BrPA while navigating through the systemic circulation. Thus far, in vitro and in vivo animal data supports this new formulation’s anticancer properties and lack of toxicity.
“To develop powerful, effective and safe anti-cancer agents by disrupting tumor metabolism.”